To say the word “Keppra,” is to invite instant controversy. For some people it works, for some it doesn’t and for others, it’s a living nightmare.
Yet two different studies found that clinically significant behavioral consequences of Keppra were eight percent, no higher, and maybe even lower, than those reported for other new antiepileptic drugs.
John Gates, M.D., lead investigator of the adult study, neurologist at Minnesota Epilepsy Group and clinical professor of neurology at the University of Minnesota said: “The efficacy of Keppra in treating seizures, coupled with our findings of its low side-effect profile, makes it an option that should be considered, especially for those who have struggled with other treatments.”
Interestingly, both studies evaluated patients with epilepsy who were proven to be drug resistant to other medications.
When Kepprawas approved as an add-on medicine for partial seizures, including partial seizures with secondary generalization, at the time, it…
View original post 1,197 more words